Fig. 4

Tumor growth and survival time of the HPV16, 18 and 58 tumor-bearing mice. A Tumor volume in each group of mice in the HPV16 (TC-1 cells) group. Tumor volume in vaccine group, AD-NC group and PBS group were significant (P < 0.05). B Tumor volume in each group of mice in the HPV18 (U14/LV-HPV18 E6E7 cells) group. Tumor volume in vaccine group, AD-NC group and PBS group were significant (P < 0.05). C Tumor volume in each group of mice in the HPV58 (U14/LV-HPV58 E6E7 cells) group. Tumor volume in vaccine group, AD-NC group and PBS group were significant (P < 0.05). D Tumor weight in each group of mice in the HPV16 (TC-1 cells) group. Tumor weight in vaccine group (11.4 ± 0.548 g), AD-NC group (8.2 ± 0.447 g) and PBS group (8.0 ± 0.707 g) were significant (P < 0.05). E Tumor weight in each group of mice in the HPV18 (U14/LV-HPV18 E6E7 cells) group. Tumor weight in vaccine group (11.2 ± 0.447 g), AD-NC group (7.8 ± 0.447 g) and PBS group (7.6 ± 0.547 g) were significant (P < 0.05). F Tumor weight in each group of mice in the HPV58 (U14/LV-HPV58 E6E7 cells) group. Tumor weight in vaccine group (12.2 ± 0.837 g), AD-NC group (9.6 ± 0.548 g) and PBS group (9.6 ± 1.140 g) were significant (P < 0.05). G Percent survival in each group of mice in the HPV16 (TC-1 cells) group. Percent survival in vaccine group, AD-NC group and PBS group were significant (P < 0.05). H Percent survival in each group of mice in the HPV18 (U14/LV-HPV18 E6E7 cells) group. Percent survival in vaccine group, AD-NC group and PBS group were significant (P < 0.05). (I) Percent survival in each group of mice in the HPV58 (U14/LV-HPV58 E6E7 cells) group. Percent survival in vaccine group, AD-NC group and PBS group were significant (P < 0.05)